Amvuttra (Vutrisiran) for Amyloidosis

Overview
Amvuttra is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with hereditary transthyretin-mediated (hATTR) amyloidosis who have polyneuropathy (nerve damage). Amvuttra is also approved to treat cardiomyopathy (heart muscle disease) caused by either wild-type or hereditary transthyretin-mediated amyloidosis in adults. For cardiomyopathy, the goal of treatment is to reduce cardiovascular death, hospitalizations, and urgent heart failure visits. Amvuttra is also known by its drug name, vutrisiran.

Amvuttra is part of a class of medications called small interfering ribonucleic acids (siRNA). It is believed to work by blocking the production of abnormal transthyretin (TTR) proteins, which helps reduce the buildup of amyloid deposits in the body.

How do I take it?
Prescribing information states that Amvuttra is given as a subcutaneous (under the skin) injection by a health care professional once every three months. It is available in a prefilled syringe containing a single 25-milligram dose. Amvuttra should be administered exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Amvuttra include pain in the extremities (arms and legs), arthralgia (joint pain), dyspnea (difficulty breathing), and decreased vitamin A levels.

Rare but serious side effects may include vitamin A deficiency. People taking Amvuttra may require a daily vitamin A supplement and should report any vision changes to their doctor, as these may be signs of deficiency.

For more details about this treatment, visit:

Amvuttra (Vutrisiran) Injection, for Subcutaneous Use — Alnylam